A retreatment study to determine the efficacy of MAVIRET (Glecaprevir/Pibrentasvir) and generic sofosbuvir for 16 weeks in hepatitis C patients with NS5A resistance who did not respond to previous VIEKIRA PAK or MAVIRET or ZEPATIER treatment
Latest Information Update: 23 Aug 2022
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 26 Jun 2022 Status changed from not yet recruiting to recruiting as per results presented at The International Liver Congress 2022
- 26 Jun 2022 Results presented at The International Liver Congress 2022
- 11 Aug 2020 New trial record